BCMA Combinations in Multiple Myeloma
Too many loved ones live with uncertainty.
Let’s find answers.
Multiple myeloma is the second most common blood cancer in the US. It originates in the bone marrow and is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow and other disease sites. Multiple myeloma is currently incurable for most patients as relapses occur despite the availability of several treatment options.
Let’s try a team approach
Several BCMA-targeted therapies have demonstrated promising clinical activity in patients with multiple myeloma. We believe that by inhibiting gamma secretase with nirogacestat, membrane-bound BCMA can be preserved, thereby increasing target density while simultaneously reducing levels of soluble BCMA, which may interfere with BCMA-directed therapies. In preclinical models of human multiple myeloma, nirogacestat has shown the ability to meaningfully enhance the activity of BCMA-targeted therapies. We are currently studying nirogacestat in multiple myeloma patients through clinical collaborations with industry-leading developers of BCMA therapies.
Nirogacestat + BLENREP
A Phase 2 randomized DREAMM-5 study is evaluating low-dose belamaf in combination with nirogacestat in patients with relapsed or refractory multiple myeloma. In addition, two new sub-studies evaluating belamaf plus nirogacestat in combination with standard of care agents in patients with relapsed or refractory multiple myeloma have been initiated and are dosing patients: sub-study 6 (belamaf plus nirogacestat plus lenalidomide plus dexamethasone) and sub-study 7 (belamaf plus nirogacestat plus pomalidomide plus dexamethasone).
Nirogacestat + Teclistamab
A Phase 1 clinical trial is evaluating nirogacestat in combination with Janssen’s teclistamab, an investigational bispecific antibody targeting BCMA and CD3, in patients with relapsed or refractory multiple myeloma.
Nirogacestat + Elranatamab
A Phase 1b/2 clinical trial is evaluating nirogacestat in combination with Pfizer’s elranatamab, an investigational BCMA CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma.
Nirogacestat + SEA-BCMA
A Phase 1 clinical trial is planned to evaluate nirogacestat in combination with Seagen’s SEA-BCMA, an investigational monoclonal antibody targeting BCMA, in patients with relapsed or refractory multiple myeloma.
Nirogacestat + ABBV-383
A Phase 1b clinical trial is planned to evaluate nirogacestat in combination with AbbVie’s ABBV-383, an investigational CD3 bispecific antibody directed against BCMA, in patients with relapsed or refractory multiple myeloma.
Nirogacestat + REGN5458
A Phase 1b clinical trial is planned to evaluate nirogacestat in combination with Regeneron’s investigational BCMAxCD3 bispecific antibody, linvoseltamab (REGN5458), in patients with relapsed or refractory multiple myeloma.